Flexible and Stretchable Bioelectronics

Chandani Chitrakar(University of North Texas), Melanie Ecker(University of North Texas), Lauren Adegoke(University of North Texas), Eric Hedrick(Florida Hospital Cancer Institute)

Materials

February 23, 2022

10.3390/ma15051664

Cited by 62

Related Papers

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2013|2.2k

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

|Journal of Clinical Oncology|2012|1.1k

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

|Journal of Clinical Oncology|2008|695

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

|Journal of Clinical Oncology|2008|623

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

|The Lancet Oncology|2018|614